DSIP vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide
A neuropeptide that promotes deep delta wave sleep. First isolated from rabbit brains in 1977. Used for sleep optimization and stress reduction.
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Key Comparison Insights
- SS-31 is FDA approved, while DSIP remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to DSIP (Human Trials).
Detailed Comparison
| Attribute | DSIP | SS-31 |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | DSIP acts on various neurotransmitter systems including serotonin, dopamine, and GABA. It modulates cortisol secretion, has stress-protective effects, and promotes delta wave (deep sleep) patterns without suppressing REM sleep. | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. |
| Common Dosing | 100-250 mcg before bed Once daily, 30 min before sleep | 40 mg subcutaneous daily Once daily |
| Administration | Subcutaneous, intramuscular, or intranasal | Subcutaneous injection or IV infusion |
| Typical Duration | 2-4 weeks typical | Variable by condition |
| Best Time to Take | 30-60 minutes before bed | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show improved sleep architecture, particularly increased delta wave sleep. Research demonstrates cortisol normalization effects and potential benefits for chronic pain and withdrawal symptoms. Results are mixed with some studies showing significant effects and others not. | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. |
Frequently Asked Questions: DSIP vs SS-31
What is the difference between DSIP and SS-31?
DSIP is a anti-aging peptide that a neuropeptide that promotes deep delta wave sleep. first isolated from rabbit brains in 1977. used for sleep optimization and stress reduction. SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. The main differences lie in their mechanisms of action and clinical applications.
Which is better, DSIP or SS-31?
Neither is universally "better" - the choice depends on your specific goals. DSIP is typically used for anti-aging purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can DSIP and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using DSIP and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of DSIP and SS-31 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.